WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- GeNO LLC, a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases, today announced that Kurt A. Dasse, Ph.D., currently serving as president and a member of the company's Board of Managers, has been appointed CEO of the Company. Dr. David Fine will continue to serve GeNO as executive chairman and chief scientific officer.
"Dr. Dasse has significant international experience with the use of inhaled nitric oxide to minimize the risk of right heart failure following the treatment of patients undergoing the implantation of Left Ventricular Assist Devices (LVADs). This appointment will strengthen the company's focus on developing and obtaining regulatory approvals for its innovative and cost-effective platforms for generating nitric oxide therapy in the treatment of multiple diseases and conditions," said David Fine, GeNO founder and executive chairman. "I am thrilled to hand over the role of CEO to Kurt."
"I believe GeNO is well positioned to make a significant impact on the medical treatment of patients worldwide who suffer from pulmonary and cardiac diseases," said Dasse. "I am honored and excited to lead a highly talented group at GeNO committed to delivering the next generation of inhaled nitric oxide products, including a portable solution, designed to benefit a large patient population."
Dasse, who will continue to serve on the company's Board of Managers, has spent nearly 30 years researching and developing therapies for cardiopulmonary disorders, and has developed and commercialized devices and therapies for the treatment of heart, lung and renal failure. He joined GeNO as a member of the Board of Managers in 2007, and was appointed executive vice president in 2011 and president in 2012.
In 2001 Dasse co-founded Levitronix LLC, the developer of the CentriMag LVAD system, where he became president and CEO in 2006. Earlier in his career, Dasse was chief scientist and vice president of Thermo Electron Corporation's $700-million Biomedical Group. He was also one of the founding officers of Thermo Cardiosystems and played a key role in commercializing one of the first implantable ventricular assist systems for end-stage heart failure patients. Dasse received his doctorate in physiology from Boston University and his bachelor's degree in biology from the University of Massachusetts. He has written more than 100 journal articles and multiple book chapters, and holds numerous patents.
ABOUT GENO LLC
GeNO LLC is a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases. GeNO is currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. GeNO's technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians and other end-users with a user-friendly solution.
CONTACT: Brian Heffron, firstname.lastname@example.org
SOURCE GeNO LLC